Skip to content
Home/Companies/Biotech/Ervimmune
Ervimmune

Ervimmune

Biotech·France·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Ervimmune?

Ervimmune is a French Biotech company, currently owned by Seventure Partners since 2022.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Seventure Partners
Investor
Seventure Partners
Health for Life Capital · 2014 · VC

Key facts

HQFrance
SectorBiotech
Websiteervimmune.com

More from Health for Life Capital

Other portfolio companies in the same fund.

Clinical Microbiomics
Active
Kainova Therapeutics
Kainova Therapeutics
Active
BiotechCanada· 2026
MaaT Pharma
MaaT Pharma
Active
BiotechFrance· 2026
Microbiotica
Microbiotica
Active
BiotechUK· 2026
Standing Ovation
Active
BiotechFrance· 2026
Sunrise
Sunrise
Active
MedTechBelgium· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Ervimmune?

Ervimmune is currently owned by Seventure Partners, through Health for Life Capital, since 2022.

When did Seventure Partners acquire Ervimmune?

Seventure Partners acquired Ervimmune in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue